Gene therapeutic DNA vector based on gene therapeutic DNA vector VTvaf17, carrying the target gene selected from the group of genes BMP-2, BMP-7, OPG, PDGFA, PDGFB, to increase the expression level of these target genes, method for its preparation and use, strain Escherichia coli SCS110-AF / VTvaf17-BMP-2, or Escherichia coli SCS110-AF / VTvaf17-BMP-7, or Escherichia coli SCS110-AF / VTvaf17-OPG, or Escherichia coli SCS110-AF / VTvaf17-PDGFA, or Escherichia coli SCSS1 -AF / VTvaf17-PDGFB carrying a gene therapy DNA vector, a method for producing it, a method for the industrial production of a gene therapy DNA vector

摘要

The invention is related to genetic engineering and can be used in biotechnology, medical science and agriculture to create gene therapy medicinal products. Gene therapy DNA vector based on gene therapy DNA vector VTvaflV carrying the target gene selected from a group of genes comprising BMP-2, BMP- 7, OPG, PDGFA, PDGFB to increase the expression level of this target gene In humans and animals is suggested. Wherein, gene therapy DNA vector VTvafl7-BMP-2, or VTvafl7-BMP-7, or VTvafl7-OPG, or VTvafl7-PDGFA, or VTvafl7-PDGFB has nucleotide sequence SEQ ID No. 1 or SEQ ID No. 2 or SEQ ID No. 3 or SEQ ID No. 4 or SEQ ID No. 5, respectively. The gene therapy DNA vector does not contain nucleotide sequences of viral origin and there are no antibiotic resistance genes, providing the possibility of its safe use for genetic therapy in humans and animals. A method of production of the specified vector, the method of use of the vector, Escherichia coli strain carrying the specified vector, as well as a method of production of the specified vector on an industrial scale are also suggested.